Masimo Corporation $MASI Shares Sold by Amundi

Amundi trimmed its stake in shares of Masimo Corporation (NASDAQ:MASI) by 63.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,167 shares of the medical equipment provider’s stock after selling 70,314 shares during the period. Amundi owned about 0.08% of Masimo worth $6,273,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA grew its holdings in Masimo by 13.4% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,967,838 shares of the medical equipment provider’s stock worth $327,842,000 after acquiring an additional 232,671 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in Masimo by 0.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,673,252 shares of the medical equipment provider’s stock worth $278,764,000 after acquiring an additional 10,876 shares during the period. Durable Capital Partners LP acquired a new stake in Masimo in the first quarter valued at approximately $187,528,000. Alyeska Investment Group L.P. grew its holdings in Masimo by 24.9% in the first quarter. Alyeska Investment Group L.P. now owns 722,534 shares of the medical equipment provider’s stock valued at $120,374,000 after purchasing an additional 143,899 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Masimo by 8.6% in the first quarter. Dimensional Fund Advisors LP now owns 703,378 shares of the medical equipment provider’s stock valued at $117,172,000 after purchasing an additional 55,658 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director William R. Jellison acquired 3,000 shares of Masimo stock in a transaction that occurred on Monday, August 11th. The shares were purchased at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the transaction, the director owned 4,790 shares in the company, valued at $699,244.20. This represents a 167.60% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 9.70% of the company’s stock.

Wall Street Analysts Forecast Growth

MASI has been the topic of several research analyst reports. BTIG Research reissued a “buy” rating on shares of Masimo in a report on Thursday, August 14th. Zacks Research raised Masimo from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Wall Street Zen lowered Masimo from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Finally, Piper Sandler raised their price objective on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $193.60.

Masimo Stock Performance

NASDAQ MASI opened at $145.82 on Thursday. The company has a market cap of $7.92 billion, a PE ratio of -17.12 and a beta of 1.23. The stock’s 50 day simple moving average is $153.09 and its 200-day simple moving average is $159.81. Masimo Corporation has a 1-year low of $111.03 and a 1-year high of $194.88. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.11. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The business had revenue of $370.90 million for the quarter, compared to the consensus estimate of $368.65 million. During the same quarter last year, the business posted $0.86 earnings per share. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.